Antibodies for long term allergy protection
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
57
NCT04266028
Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy
Phase: Phase 1
Role: Lead Sponsor
Start: Feb 11, 2020
Completion: May 31, 2021
NCT06037148
Study to Evaluate Safety, Tolerability and Explorative Efficacy of DM-101PX in Birch Pollen Allergic Participants
Start: Sep 7, 2023
Completion: Mar 6, 2024
Loading map...